摘要
目的观察聚乙二醇干扰素α-2a(PEG-IFN-α)治疗丙型肝炎病毒/乙型肝炎病毒(HBV/HCV)共同感染患者的临床疗效。方法选取2011年4月至2015年12月鄂东医疗集团市中医医院收治的HBV/HCV共同感染患者40例作为HBV/HCV组,HCV感染患者45例为HCV组,两组患者均给予PEG-IFN-α联合利巴韦林治疗,比较两组患者的HCV RNA转阴情况及肝功能变化。结果 HCV组患者治疗后的转阴率为55.6%,明显高于HBV/HCV组的32.5%,差异有统计学意义(P<0.05);HCV组患者的谷草转氨酶(AST)、谷丙转氨酶(ALT)、透明质酸(HA)及HBV/HCV组患者的ALT、AST治疗后明显优于治疗前,差异均有统计学意义(P<0.05);HCV组患者的Ⅲ型前胶原(PCⅢ)及HBV/HCV组患者的PCⅢ、HA在治疗前后比较差异均无统计学意义(P>0.05),治疗后两组患者的ALT、AST、HA、PCⅢ比较差异均无统计学意义(P>0.05)。结论聚乙二醇干扰素α-2a治疗HBV/HCV单一病毒感染疗效优于共同感染。
Objective To discuss the clinical effects of PEG-IFN-α combined with ribavirin in the treatment of chronic hepatitis C virus（HCV） and hepatitis B virus（HBV） coinfection. Methods Forty patients with HCV and HBV coinfection from TCM Hospital of Eastern Hubei Medical Group between April 2011 and December 2015 were divided into the HBV/HCV group, and 45 patients with HCV infection were divided into the HCV group. Then the two groups were treated with PEG-IFN-α combined with ribavirin, and the clinical effects were contrasted between the two groups.Results The negative conversion rate after the treatment in the HCV group was 55.6%, significantly higher than 32.5%in the HBV/HCV group（P〈0.05）. Aspertate aminotransferase（AST）, alanine transaminase（ALT）, haluronic acid（HA）in the HCV group and ALT, AST in the HBV/HCV group after the treatment were significantly better than before treatment（P〈0.05）, and there was no significant difference in procollagen type Ⅲ（PCⅢ） in the HCV group and PCⅢ, HA in the HBV/HCV group before and after the treatment（P〉0.05）. No significant difference was found in ALT, AST, HA,PCⅢ between the two groups after the treatment（P〉0.05）. Conclusion PEG-IFN-α combined with ribavirin has better clinical effects in the treatment of HCV or HBV single infection than coinfection.
出处
《海南医学》
CAS
2017年第7期1061-1063,共3页
Hainan Medical Journal
